BridgeBio Oncology Therapeutics (BBOT) Income from Continuing Operations (2024 - 2026)
BridgeBio Oncology Therapeutics (BBOT) posted Income from Continuing Operations of 62087000.0 for Q1 2026, up 27.96% sequentially from 86179000.0 in Q4 2025, and down 193.59% YoY from 66341452.06 in Q1 2025.
BridgeBio Oncology Therapeutics (BBOT) Income from Continuing Operations (2024 - 2026) Analysis & Trends
BridgeBio Oncology Therapeutics has reported Income from Continuing Operations for 3 years, with the latest figure at 62087000.0 in Q1 2026.
- Quarterly Income from Continuing Operations fell 193.59% year-over-year to 62087000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 232334849.0 (down 130.54% YoY) and the FY2025 annual result came in at 233001000.0, down 98.14% from the prior year.
- Income from Continuing Operations grew to 62087000.0 in Q1 2026 per BBOT's latest filing, from 86179000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 2289936.0 in Q2 2024 and troughed at 86179000.0 in Q4 2025.
- A 3-year average of 36886148.22 and a median of 21147732.0 in 2025 frame the typical range for Income from Continuing Operations.
- The widest YoY moves for Income from Continuing Operations: up 32.97% in 2025, down 1955.37% in 2025.
- Over 3 years, Income from Continuing Operations stood at 64813113.0 in 2024, then plunged by 32.97% to 86179000.0 in 2025, then grew by 27.96% to 62087000.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 62087000.0, 86179000.0, and 85022000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,096.02 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | BridgeBio Oncology Therapeutics | 726.38 Mn | 500.67 Mn | - | -70.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -70.81 Mn |
| Mar 31, 2026 | -62.09 Mn |
| Dec 31, 2025 | -86.18 Mn |
| Sep 30, 2025 | -85.02 Mn |
| Jun 30, 2025 | 953,151.00 |
| Mar 31, 2025 | -21.15 Mn |
| Dec 31, 2024 | -64.81 Mn |
| Sep 30, 2024 | -17.11 Mn |
| Jun 30, 2024 | 2.29 Mn |
| Mar 31, 2024 | 1.14 Mn |